CJC-1295

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), designed with a longer half-life to support prolonged GH secretion in research settings. It is studied for its pharmacokinetic improvements over natural GHRH, especially when combined with GHRP peptides. The DAC modification allows for extended half-life and reduced injection frequency while significantly elevating IGF-1 levels.

• GHRH receptor agonist
• Stimulates growth hormone secretion
• Extends pulsatile GH release via DAC binding to albumin

• unit: mcg

  low dose: 50

  frequency: 2-3 times daily (typically before meals or at bedtime)

  high dose: 150

  standard dose: 100

  administration route: Subcutaneous (SQ)

• CJC-1295 DAC: 500 mcg 1–2x per week. CJC-1295 no DAC: 50-150 mcg before bed or post-workout for 5 days on 2 days off. Recommended cycle: 8–12 weeks with equal time off.

common: ["Transient flushing, headache, or water retention during initial titration"]

sequence: Modified GHRH sequence with DAC

half life: 6–8 days with DAC (versus 30 minutes without)

degradation: Slow enzymatic breakdown via albumin-binding system

molecular weight: 3647.2

molecular formula: C165H269N47O46

tissue specificity: Targets pituitary somatotrophs to stimulate pulsatile GH secretion

• Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults.clinicalPMID 16352683 ↗
• hGRF1-29-albumin bioconjugates: identification of CJC-1295 as a long-lasting GRF analog.mechanismPMID 15817669 ↗
• Once-daily CJC-1295 normalizes growth in the GHRH knockout mouse.preclinicalPMID 16822960 ↗